突变2级胶质瘤患者的疗效和安全性。根据ASCO官网公布的摘要,在预定的第二次中期分析中,vorasidenib达到无进展生存期(PFS)的主要终点(中位PFS:27.7个月 vs 11.1个月)以及下一次干预时间(TTNI)的关键性次要终点(中位TTNI:尚未达到 vs 17.8个月),将患者疾病进展或死亡风险降低61%。施维雅此前发布的新闻稿指出,这是超过20年来在
新辅助治疗中,选择性使用5FUCRT的FOLFOX化疗不劣于5FUCRT。在中位随访58个月时,干预组DFS为80.8%(vs 78.6%),局部无复发生存期(LRFS)率为98.2%(vs 98.4%),总生存(OS)率为89.5%(vs 90.2%)。参考资料:[1]ASCO大会官网.From https://conferences.asco.org/am/abstracts[2] Servier Presents Transformational Data from Pivotal Phase 3 INDIGO Trial of Vorasidenib in Recurrent or Residual Grade 2 IDH-Mutant Diffuse Glioma. Retrieved June 4, 2023, from https://www.prnewswire.com/news-releases/servier-presents-transformational-data-from-pivotal-phase-3-indigo-trial-of-vorasidenib-in-recurrent-or-residual-grade-2-idh-mutant-diffuse-glioma-301841862.html[3] ASCO: Seagen's top-selling drug under threat as Bristol Myers'
Opdivo beats Adcetris in lymphoma. Retrieved June 4, 2023 from https://www.fiercepharma.com/pharma/seagens-top-selling-drug-under-threat-bristol-myers-opdivo-beats-adcetris-lymphoma[4] AGRISSO® achieved unprecedented survival in early-stage EGFR-mutated lung cancer, with 88% of patients alive at five years in ADAURA Phase III trial. Retrieved June 4, 2023, from https://www.businesswire.com/news/home/20230604005028/end bevacizumab in patients with advanced ovarian cancer without tumour BRCA mutations in the DUO-O Phase III trial. Retrieved June 3, 2023, from https://www.astrazeneca.com/media-centre/press-releases/2023/lynparza-and-imfinzi-combination-reduced-risk-of-disease-progression-or-death-vs-chemotherapy-and-bevacizumab-in-patients-with-advanced-ovarian-cancer-without-tumour-brca-mutations-in-the-duo-o-phase-iii-trial.html本文来自药明康德内容团队,欢迎个人转发至朋友圈,谢绝媒体或机构未经授权以任何形式转载至其他平台。转载授权请在「医药观澜」微信公众号留言联系我们。其他合作需求,请联系wuxi_media@wuxiapptec.com。免责声明:药明康德内容团队专注介绍全球生物医药健康研究进展。本文仅作信息交流之目的,文中观点不代表药明康德立场,亦不代表药明康德支持或反对文中观点。本文也不是治疗方案推荐。如需获得治疗方案指导,请前往正规医院就诊。